Merck's Stock Price-to-Earnings Ratio Hits New High Amid Pipeline Setbacks

Merck's (MRK) stock has seen a significant increase in its forward price-to-earnings ratio over the past year, rising to nearly 17x from around 9x.

This comes as the company faces setbacks with some of its pipeline projects. Recently, Merck and Daiichi Sankyo withdrew their application for accelerated U.S. approval of ifinatamab deruxtecan, an investigational cancer drug, after the FDA indicated that the supporting data fell short.

Despite these challenges, Merck's CEO Robert Davis remains optimistic about the company's pipeline, stating that recent data readouts have 'all pretty much turned over positive' and that there is upside to the estimated $70 billion in non-risk-adjusted commercial opportunity from its pipeline by the mid-2030s.

The withdrawal of the ifinatamab deruxtecan application came 11 days after Davis's comments, with shares trading at $148.74 on September 25. The company's pipeline includes several promising projects, including TERN-701 and MK-2010, which are not included in the estimated $70 billion figure.